Enhertu posts survival boost in second-line gastric cancer trial
Daiichi Sankyo (TYO: 4568) and AstraZeneca (LSE: AZN) have released detailed Phase III results that could help position their HER2-targeting drug Enhertu (trastuzumab deruxtecan) as the second-line standard of care for advanced gastric cancer.
The data, presented at the American Society of Clinical Oncology meeting, came from the DESTINY-Gastric04 trial and were compelling enough to justify the study’s early unblinding. In patients with HER2-positive, inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma, Enhertu significantly extended overall survival compared to the combination of Cyramza (ramucirumab) and paclitaxel.
According to the interim analysis, median overall survival was 14.7 months with Enhertu, compared with 11.4 months for the comparator group, translating to a 30% reduction in the risk of death. Progression-free survival was also longer, at 6.7 months versus 5.6 months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze